权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Multi-targeted RNAi Therapeutic for Treatment of Breast Cancer

多靶点 RNAi 治疗乳腺癌

基本信息

批准号：
7612580
负责人：
Patrick Y Lu
金额：
$ 22.8万
依托单位：
SIRNAOMICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-22 至 2009-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7612580
关键词：
Adjuvant Therapy Animal Model Antisense Oligonucleotides Avastin Binding Biological Models Breast Breast Cancer Cell Breast Cancer Treatment Cancer Death Rates Cancer Etiology Cells Cessation of life Cleaved cell Clinical Clinical Trials Complex Cultured Cells Detection Development Disease Disease model Dose Double-Stranded RNA Drug Industry EGFR gene Early Diagnosis Enzyme-Linked Immunosorbent Assay Epidermal Growth Factor Receptor Gene Silencing Gene Targeting Genes Growth Head and Neck Cancer Head and Neck Neoplasms High Dose Chemotherapy Histidine Human Individual Keratitis Life Lysine Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Mediating Messenger RNA Modeling Monoclonal Antibodies Mus Nucleotides Operative Surgical Procedures Outcome Pathway interactions Patients Polymers Proteins Public Health RNA Interference RNA-Induced Silencing Complex Radiation therapy Reverse Transcriptase Polymerase Chain Reaction Ribonuclease III Role Sentinel Lymph Node Biopsy Small Interfering RNA Standards of Weights and Measures Stem cell transplant Technology Testing Therapeutic Therapeutic Intervention Treatment Protocols Tumor Angiogenesis Tyrosine Kinase Inhibitor Vascular Endothelial Growth Factors Woman Xenograft Model antiangiogenesis therapy c-erbB-1 Proto-Oncogenes chemotherapy clinical effect day dosage endonuclease hormone therapy human DICER1 protein human FRAP1 protein in vivo inhibitor/antagonist malignant breast neoplasm nuclease ocular angiogenesis response single molecule success therapeutic target time interval tumor tumor growth tumor xenograft

项目摘要

DESCRIPTION (provided by applicant): Millions of women have been treated for or are living with breast cancer, and tens of thousands of women are expected to die from the disease each year. As breast cancer disease remains the second leading cause of cancer death in women (after lung cancer), different types of treatment have been developed including surgery, radiation therapy, chemotherapy and hormone therapy. New types of therapies are also going through development and trials in order to treat this malignant disease. This proposal is to use the breakthrough RNAi technology to develop a multi-targeted therapeutics to treat breast cancer. This proposed study is to take advantage of the HKP carriers with siRNA cocktails targeting three specific genes (EGFR, Raf-1 and mTOR) as an RNAi therapeutic protocol for treatment of breast cancer, and to combine the siRNA cocktail with Avastin to mimic a clinical regimen. The success of this approach will have tremendous scientific and therapeutic impacts for combating breast cancer and many other cancers. PUBLIC HEALTH RELEVANCE: As breast cancer disease remains the second leading cause of cancer death in women (after lung cancer), various types of treatment have been developed including surgery, radiation therapy, chemotherapy and hormone therapy. Using the breakthrough RNAi technology, we are developing a multi-targeted therapeutics to treat breast cancer. This proposed study is to take advantage of the HKP carriers with siRNA cocktails targeting three specific genes as an RNAi therapeutic protocol for treatment of breast cancer, and to combine the siRNA cocktail with Avastin to mimic a clinical regimen. The outcome of the project is expected to be of significant value for the patients and pharmaceutical industry.

描述(申请人提供)：数百万女性因乳腺癌接受治疗或与之生活在一起，预计每年有数万名女性死于这种疾病。由于乳腺癌仍然是女性癌症死亡的第二大原因(仅次于肺癌)，已经开发了不同类型的治疗方法，包括手术、放射治疗、化疗和激素治疗。为了治疗这种恶性疾病，新型疗法也在进行开发和试验。这项提议是利用突破性的RNAi技术来开发一种治疗乳腺癌的多靶点疗法。这项拟议的研究旨在利用针对三个特定基因(EGFR、Raf-1和mTOR)的siRNA鸡尾酒作为RNAi治疗乳腺癌的方案，并将siRNA鸡尾酒与阿瓦斯丁结合以模拟临床方案。这种方法的成功将对抗击乳腺癌和许多其他癌症产生巨大的科学和治疗影响。公共卫生相关性：由于乳腺癌仍然是女性癌症死亡的第二大原因(仅次于肺癌)，已开发出各种类型的治疗方法，包括手术、放射治疗、化疗和激素治疗。利用突破性的RNAi技术，我们正在开发一种治疗乳腺癌的多靶点疗法。这项拟议的研究旨在利用针对三个特定基因的siRNA鸡尾酒作为RNAi治疗乳腺癌的方案，并将siRNA鸡尾酒与阿瓦斯丁结合以模拟临床方案。预计该项目的成果将对患者和制药行业具有重要价值。